- Home
- INCY vs JLL Comparison
INCY vs JLL Comparison
Compare INCY & JLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- JLL
- Stock Information
- Founded
- INCY 1991
- JLL 1997
- Country
- INCY United States
- JLL United States
- Employees
- INCY N/A
- JLL N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- JLL Real Estate
- Sector
- INCY Health Care
- JLL Finance
- Exchange
- INCY Nasdaq
- JLL Nasdaq
- Market Cap
- INCY 13.4B
- JLL 11.0B
- IPO Year
- INCY 1993
- JLL 1997
- Fundamental
- Price
- INCY $69.50
- JLL $259.15
- Analyst Decision
- INCY Hold
- JLL Strong Buy
- Analyst Count
- INCY 20
- JLL 7
- Target Price
- INCY $73.81
- JLL $305.00
- AVG Volume (30 Days)
- INCY 2.1M
- JLL 476.3K
- Earning Date
- INCY 07-29-2025
- JLL 08-05-2025
- Dividend Yield
- INCY N/A
- JLL N/A
- EPS Growth
- INCY N/A
- JLL 78.40
- EPS
- INCY 0.10
- JLL 11.07
- Revenue
- INCY $4,413,226,000.00
- JLL $24,054,800,000.00
- Revenue This Year
- INCY $13.48
- JLL $10.02
- Revenue Next Year
- INCY $10.35
- JLL $8.25
- P/E Ratio
- INCY $701.37
- JLL $23.12
- Revenue Growth
- INCY 17.13
- JLL 13.63
- 52 Week Low
- INCY $53.56
- JLL $194.36
- 52 Week High
- INCY $83.95
- JLL $288.50
- Technical
- Relative Strength Index (RSI)
- INCY 51.24
- JLL 65.91
- Support Level
- INCY $66.74
- JLL $243.94
- Resistance Level
- INCY $71.50
- JLL $260.00
- Average True Range (ATR)
- INCY 1.76
- JLL 5.58
- MACD
- INCY -0.34
- JLL 1.85
- Stochastic Oscillator
- INCY 20.59
- JLL 83.17
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.